Skip to main content

ADVERTISEMENT

Stefan Schreiber

BACKGROUND: BI 695501 has demonstrated bioequivalence to both the US-licensed and EU-approved adalimumab reference product (RP) in rheumatoid arthritis. The aim of this head-to-head trial...
12/13/2019